ZENTEK LTD. (ZAY0) - Net Assets
Based on the latest financial reports, ZENTEK LTD. (ZAY0) has net assets worth €12.34 Million EUR (≈ $14.43 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€17.38 Million ≈ $20.32 Million USD) and total liabilities (€5.04 Million ≈ $5.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore ZAY0 current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €12.34 Million |
| % of Total Assets | 70.99% |
| Annual Growth Rate | -29.19% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.17 |
ZENTEK LTD. - Net Assets Trend (2022–2025)
This chart illustrates how ZENTEK LTD.'s net assets have evolved over time, based on quarterly financial data. Check ZENTEK LTD. tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for ZENTEK LTD. (2022–2025)
The table below shows the annual net assets of ZENTEK LTD. from 2022 to 2025. For live valuation and market cap data, see ZAY0 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €14.75 Million ≈ $17.24 Million |
-26.89% |
| 2024-03-31 | €20.17 Million ≈ $23.58 Million |
-33.61% |
| 2023-03-31 | €30.38 Million ≈ $35.52 Million |
-26.87% |
| 2022-03-31 | €41.55 Million ≈ $48.58 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ZENTEK LTD.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3167387500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €98.60 Million | 668.52% |
| Total Equity | €14.75 Million | 100.00% |
ZENTEK LTD. Competitors by Market Cap
The table below lists competitors of ZENTEK LTD. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Campina Ice Cream Industry Tbk PT
JK:CAMP
|
$58.62 Million |
|
Mesa Air Group Inc
NASDAQ:MESA
|
$58.63 Million |
|
Credo Brands Marketing Limited
NSE:MUFTI
|
$58.64 Million |
|
Mastermyne Group Ltd
AU:MYE
|
$58.64 Million |
|
Dongkuk Structures & Construction Company Limited
KQ:100130
|
$58.58 Million |
|
Labiana Health S.A.
MC:LAB
|
$58.58 Million |
|
Samart Telcoms Public Company Limited
BK:SAMTEL
|
$58.56 Million |
|
Wp Energy Public Company Limited
BK:WP
|
$58.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ZENTEK LTD.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 20,173,211 to 14,749,447, a change of -5,423,764 (-26.9%).
- Net loss of 10,039,658 reduced equity.
- New share issuances of 3,069,950 increased equity.
- Other factors increased equity by 1,545,944.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.04 Million | -68.07% |
| Share Issuances | €3.07 Million | +20.81% |
| Other Changes | €1.55 Million | +10.48% |
| Total Change | €- | -26.89% |
Book Value vs Market Value Analysis
This analysis compares ZENTEK LTD.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.11x to 3.30x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | €0.42 | €0.47 | x |
| 2023-03-31 | €0.31 | €0.47 | x |
| 2024-03-31 | €0.20 | €0.47 | x |
| 2025-03-31 | €0.14 | €0.47 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ZENTEK LTD. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -68.07%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1150.68%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.25x
- Recent ROE (-68.07%) is below the historical average (-62.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -76.28% | -9330.95% | 0.01x | 1.08x | €-35.85 Million |
| 2023 | -47.44% | -19784.87% | 0.00x | 1.10x | €-17.45 Million |
| 2024 | -58.02% | -39254.06% | 0.00x | 1.12x | €-13.72 Million |
| 2025 | -68.07% | -1150.68% | 0.05x | 1.25x | €-11.51 Million |
Industry Comparison
This section compares ZENTEK LTD.'s net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $5,424,347,981
- Average return on equity (ROE) among peers: -6.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ZENTEK LTD. (ZAY0) | €12.34 Million | -76.28% | 0.41x | $58.59 Million |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $792.27 Million | 18.89% | 0.82x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.67 Billion | 11.61% | 1.89x | $15.47 Billion |
| MEDIMI AB AK (79T) | $15.25 Million | -101.01% | 0.19x | $365.27K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-938.43K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $999.59 Million |
| Carl Zeiss Meditec AG (AFX) | $1.45 Billion | 8.44% | 0.39x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.03 Billion | 14.48% | 0.39x | $2.14 Billion |
| Bio-gate AG (BIG1) | $1.79 Million | -90.74% | 1.21x | $6.27 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $8.29 Billion | 56.75% | 3.52x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $38.15 Billion | 5.64% | 0.59x | $78.07 Billion |
About ZENTEK LTD.
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coatings under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It also… Read more